Current U.S. tariff landscape for Belgium in the pharmaceutical sector as of October 6, 2025.
For over three decades, pharmaceutical products have generally been subject to a zero-tariff policy between the U.S. and the European Union.
15%.The United States and the European Union have a trade agreement that limits tariffs on pharmaceuticals to a 15% ceiling. This came after a period of uncertainty where the US had considered higher tariffs. The Belgian pharmaceutical federation, essenscia, has voiced concerns over the new tariffs, highlighting the potential impact on Belgium's significant pharmaceutical export market to the US.
Current U.S. tariff landscape for India in the pharmaceutical sector as of October 6, 2025.
$9.8 billion to $10 billion. The US is India's largest market for pharmaceutical goods, accounting for about 35% of its total pharma exports.85-90%) are generic drugs, which are exempt from the recently announced tariffs. Branded or patented drugs, which constitute a smaller portion of exports, are impacted.Historically, the U.S. has not charged any import duty on Indian drugs.
100% tariff on the import of branded and patented pharmaceutical products.100% on branded and patented pharmaceuticals. This tariff is waived for companies that are building or expanding manufacturing facilities in the United States.The new U.S. tariff of 100% on branded and patented pharmaceuticals is not expected to have a major immediate impact on the Indian pharmaceutical industry, as the majority of its exports to the U.S. are generics. However, there are concerns about the potential for a broad interpretation of "branded generics" which could lead to delays and additional costs. The move is seen as part of a broader U.S. strategy to encourage domestic manufacturing of pharmaceuticals.
Current U.S. tariff landscape for Italy in the pharmaceutical sector as of October 6, 2025.
€122.1 billion worth of pharmaceutical products to the United States in 2024. Italy is a significant contributor to this total.For many years, pharmaceutical products from the European Union, including Italy, have been exempt from U.S. import tariffs.
15%.Under a recent trade agreement between the U.S. and the EU, tariffs on pharmaceuticals from Italy are capped at 15%. This agreement provides a level of certainty for Italian pharmaceutical exporters, although it represents a shift from the previous zero-tariff environment. The European Commission has emphasized that this 15% ceiling acts as an "insurance policy" against higher tariffs.
Current U.S. tariff landscape for the Netherlands in the pharmaceutical sector as of October 6, 2025.
€35.5 billion in pharmaceutical products annually, with a significant portion going to the U.S. The pharmaceutical sector has the highest share of exports to the U.S. from the Netherlands, at 14%.Pharmaceuticals from the Netherlands, as part of the EU, were not subject to U.S. import tariffs prior to the recent changes.
15%.The current U.S. tariff on Dutch pharmaceutical products is capped at 15% as part of a broader EU-US trade agreement. Analysts have estimated that new American tariffs on pharmaceuticals could have a significant economic impact on the Netherlands. While there was initial uncertainty about higher tariffs, the 15% cap has provided some stability for the Dutch pharmaceutical industry.
Current U.S. tariff landscape for Japan in the pharmaceutical sector as of October 6, 2025.
¥411 billion (approximately $2.7 billion) worth of pharmaceutical products to the United States.Prior to the current agreement, tariffs on pharmaceuticals from Japan varied by product.
15%. Generic pharmaceuticals and their ingredients are subject to a 0% tariff.Under a bilateral agreement, the U.S. tariff on most Japanese pharmaceutical imports is capped at 15%, and generic drugs are exempt from tariffs altogether. This provides a degree of certainty for Japanese pharmaceutical manufacturers. The agreement ensures that Japanese pharmaceutical products receive tariff treatment that is no less favorable than that applied to similar products from the EU.
Current U.S. tariff landscape for Canada in the pharmaceutical sector as of October 6, 2025.
Under the North American Free Trade Agreement (NAFTA), the predecessor to the USMCA, tariffs on pharmaceuticals were largely eliminated.
The trade of pharmaceutical products between the United States and Canada is primarily governed by the USMCA, which allows for largely tariff-free trade. The recent U.S. tariff announcements have been focused on overseas imports and have not indicated any changes to the tariff preferences for Canadian pharmaceuticals under the USMCA. Therefore, the tariff situation for pharmaceuticals remains stable between the U.S. and Canada.
Current U.S. tariff landscape for the United Kingdom in the pharmaceutical sector as of October 6, 2025.
Prior to recent announcements, pharmaceutical trade between the U.S. and the UK was not subject to significant tariffs.
100% tariff on branded and patented pharmaceutical imports.100% on branded and patented pharmaceuticals. An exemption exists for companies that are building or have manufacturing plants in the U.S.The United Kingdom is currently facing the possibility of a 100% U.S. tariff on branded and patented pharmaceutical products. Unlike the EU and Japan, the UK has not yet finalized an agreement with the U.S. on a specific tariff rate for pharmaceuticals, leaving the industry in a state of uncertainty. The UK government has expressed concern and is actively engaging with the U.S. on this issue.
Current U.S. tariff landscape for France in the pharmaceutical sector as of October 6, 2025.
€122.1 billion.Previously, U.S. tariffs on pharmaceuticals from France were generally zero, in line with the broader EU-US trade relationship.
15% is in effect for most pharmaceuticals.Pharmaceuticals from France are subject to a U.S. import tariff of up to 15%, as stipulated by the recent EU-US trade agreement. This marks a notable change from the previous duty-free status. The 15% cap provides some predictability for French pharmaceutical companies exporting to the American market.
Current U.S. tariff landscape for Denmark in the pharmaceutical sector as of October 6, 2025.
15% tariff applies to most pharmaceutical products, with possible exemptions for generics.U.S. tariffs on Danish pharmaceuticals were generally not applied prior to the recent EU-US trade agreement.
15% for most pharmaceutical products.As a member of the EU, Denmark's pharmaceutical exports to the U.S. are now subject to a tariff of up to 15%. This is a result of the recent trade agreement between the European Union and the United States. This new tariff structure creates a more predictable, albeit more costly, trade environment for the Danish pharmaceutical industry.
Current U.S. tariff landscape for Spain in the pharmaceutical sector as of October 6, 2025.
€122.1 billion in 2024.There were generally no U.S. tariffs on pharmaceutical imports from Spain prior to the recent changes.
15%.Pharmaceutical products from Spain are subject to a U.S. import tariff of up to 15% under the terms of the recent EU-US trade agreement. This represents a new cost for Spanish pharmaceutical exporters to the U.S. market. The 15% cap is seen as a measure to prevent even higher potential tariffs.
Current U.S. tariff landscape for Brazil in the pharmaceutical sector as of October 6, 2025.
Information on pre-existing tariff rates for Brazilian pharmaceuticals is not available in the search results.
There is currently no indication of any recent changes to U.S. tariffs on pharmaceutical products from Brazil. The trade relationship in this sector appears to be stable and is not mentioned in the context of the recent protectionist measures announced by the U.S. It is likely that the standard Most-Favored-Nation (MFN) tariff rates apply.
Current U.S. tariff landscape for Slovenia in the pharmaceutical sector as of October 6, 2025.
$830 million due to tariffs, which is equivalent to 1.1% of Slovenia's annual GDP.Before the recent tariffs, pharmaceuticals from Slovenia were generally not subject to U.S. import duties.
15% for most pharmaceuticals. However, due to the composition of its exports, Slovenia could face a higher effective tariff rate.Slovenia's pharmaceutical industry has been significantly impacted by U.S. tariffs, largely due to its integration with the Swiss pharmaceutical supply chain, which faces high U.S. tariffs. While Slovenia is covered by the EU-US agreement capping tariffs at 15%, the indirect effects through its trade partners have been substantial. The economic impact of these tariffs on Slovenia's highly open economy is a significant concern.
Current U.S. tariff landscape for Mexico in the pharmaceutical sector as of October 6, 2025.
Tariffs on pharmaceuticals were mostly eliminated under the North American Free Trade Agreement (NAFTA), the predecessor to the USMCA.
The trade of pharmaceutical products between the United States and Mexico is governed by the USMCA, which provides for largely tariff-free trade. The recent U.S. tariff actions have been focused on overseas imports and have not impacted the preferential treatment of pharmaceuticals from Mexico under the USMCA. Thus, the tariff situation for pharmaceuticals remains stable in the U.S.-Mexico trade relationship.
Current U.S. tariff landscape for Australia in the pharmaceutical sector as of October 6, 2025.
$1.9 billion to $2.6 billion. In 2024, pharmaceuticals were Australia's third largest export to the US.Under the Australia-United States Free Trade Agreement (AUSFTA), most pharmaceutical trade was duty-free.
100% tariff on branded and patented pharmaceutical imports.100% on branded and patented pharmaceuticals, with exemptions for companies building or operating manufacturing plants in the U.S.The announced 100% U.S. tariff on branded pharmaceuticals poses a potential threat to Australia's pharmaceutical export industry. However, the impact may be mitigated by exemptions for companies with a U.S. manufacturing footprint, such as Australia's largest pharmaceutical exporter, CSL. The Australian government is currently working to understand the full implications of these new tariffs for local exporters.
Current U.S. tariff landscape for Sweden in the pharmaceutical sector as of October 6, 2025.
€122.1 billion in pharmaceutical exports to the U.S. in 2024.U.S. tariffs on pharmaceuticals from Sweden were generally zero before the recent trade agreement.
15%.Pharmaceuticals exported from Sweden to the United States are subject to a tariff of up to 15% under the recent EU-US trade agreement. This new tariff represents a shift from the previous duty-free environment. The 15% cap provides some measure of stability for the Swedish pharmaceutical industry in its trade with the U.S.
Current U.S. tariff landscape for Belgium in the pharmaceutical sector as of October 6, 2025.
For over three decades, pharmaceutical products have generally been subject to a zero-tariff policy between the U.S. and the European Union.
15%.The United States and the European Union have a trade agreement that limits tariffs on pharmaceuticals to a 15% ceiling. This came after a period of uncertainty where the US had considered higher tariffs. The Belgian pharmaceutical federation, essenscia, has voiced concerns over the new tariffs, highlighting the potential impact on Belgium's significant pharmaceutical export market to the US.
Current U.S. tariff landscape for India in the pharmaceutical sector as of October 6, 2025.
$9.8 billion to $10 billion. The US is India's largest market for pharmaceutical goods, accounting for about 35% of its total pharma exports.85-90%) are generic drugs, which are exempt from the recently announced tariffs. Branded or patented drugs, which constitute a smaller portion of exports, are impacted.Historically, the U.S. has not charged any import duty on Indian drugs.
100% tariff on the import of branded and patented pharmaceutical products.100% on branded and patented pharmaceuticals. This tariff is waived for companies that are building or expanding manufacturing facilities in the United States.The new U.S. tariff of 100% on branded and patented pharmaceuticals is not expected to have a major immediate impact on the Indian pharmaceutical industry, as the majority of its exports to the U.S. are generics. However, there are concerns about the potential for a broad interpretation of "branded generics" which could lead to delays and additional costs. The move is seen as part of a broader U.S. strategy to encourage domestic manufacturing of pharmaceuticals.
Current U.S. tariff landscape for Italy in the pharmaceutical sector as of October 6, 2025.
€122.1 billion worth of pharmaceutical products to the United States in 2024. Italy is a significant contributor to this total.For many years, pharmaceutical products from the European Union, including Italy, have been exempt from U.S. import tariffs.
15%.Under a recent trade agreement between the U.S. and the EU, tariffs on pharmaceuticals from Italy are capped at 15%. This agreement provides a level of certainty for Italian pharmaceutical exporters, although it represents a shift from the previous zero-tariff environment. The European Commission has emphasized that this 15% ceiling acts as an "insurance policy" against higher tariffs.
Current U.S. tariff landscape for the Netherlands in the pharmaceutical sector as of October 6, 2025.
€35.5 billion in pharmaceutical products annually, with a significant portion going to the U.S. The pharmaceutical sector has the highest share of exports to the U.S. from the Netherlands, at 14%.Pharmaceuticals from the Netherlands, as part of the EU, were not subject to U.S. import tariffs prior to the recent changes.
15%.The current U.S. tariff on Dutch pharmaceutical products is capped at 15% as part of a broader EU-US trade agreement. Analysts have estimated that new American tariffs on pharmaceuticals could have a significant economic impact on the Netherlands. While there was initial uncertainty about higher tariffs, the 15% cap has provided some stability for the Dutch pharmaceutical industry.
Current U.S. tariff landscape for Japan in the pharmaceutical sector as of October 6, 2025.
¥411 billion (approximately $2.7 billion) worth of pharmaceutical products to the United States.Prior to the current agreement, tariffs on pharmaceuticals from Japan varied by product.
15%. Generic pharmaceuticals and their ingredients are subject to a 0% tariff.Under a bilateral agreement, the U.S. tariff on most Japanese pharmaceutical imports is capped at 15%, and generic drugs are exempt from tariffs altogether. This provides a degree of certainty for Japanese pharmaceutical manufacturers. The agreement ensures that Japanese pharmaceutical products receive tariff treatment that is no less favorable than that applied to similar products from the EU.
Current U.S. tariff landscape for Canada in the pharmaceutical sector as of October 6, 2025.
Under the North American Free Trade Agreement (NAFTA), the predecessor to the USMCA, tariffs on pharmaceuticals were largely eliminated.
The trade of pharmaceutical products between the United States and Canada is primarily governed by the USMCA, which allows for largely tariff-free trade. The recent U.S. tariff announcements have been focused on overseas imports and have not indicated any changes to the tariff preferences for Canadian pharmaceuticals under the USMCA. Therefore, the tariff situation for pharmaceuticals remains stable between the U.S. and Canada.
Current U.S. tariff landscape for the United Kingdom in the pharmaceutical sector as of October 6, 2025.
Prior to recent announcements, pharmaceutical trade between the U.S. and the UK was not subject to significant tariffs.
100% tariff on branded and patented pharmaceutical imports.100% on branded and patented pharmaceuticals. An exemption exists for companies that are building or have manufacturing plants in the U.S.The United Kingdom is currently facing the possibility of a 100% U.S. tariff on branded and patented pharmaceutical products. Unlike the EU and Japan, the UK has not yet finalized an agreement with the U.S. on a specific tariff rate for pharmaceuticals, leaving the industry in a state of uncertainty. The UK government has expressed concern and is actively engaging with the U.S. on this issue.
Current U.S. tariff landscape for France in the pharmaceutical sector as of October 6, 2025.
€122.1 billion.Previously, U.S. tariffs on pharmaceuticals from France were generally zero, in line with the broader EU-US trade relationship.
15% is in effect for most pharmaceuticals.Pharmaceuticals from France are subject to a U.S. import tariff of up to 15%, as stipulated by the recent EU-US trade agreement. This marks a notable change from the previous duty-free status. The 15% cap provides some predictability for French pharmaceutical companies exporting to the American market.
Current U.S. tariff landscape for Denmark in the pharmaceutical sector as of October 6, 2025.
15% tariff applies to most pharmaceutical products, with possible exemptions for generics.U.S. tariffs on Danish pharmaceuticals were generally not applied prior to the recent EU-US trade agreement.
15% for most pharmaceutical products.As a member of the EU, Denmark's pharmaceutical exports to the U.S. are now subject to a tariff of up to 15%. This is a result of the recent trade agreement between the European Union and the United States. This new tariff structure creates a more predictable, albeit more costly, trade environment for the Danish pharmaceutical industry.
Current U.S. tariff landscape for Spain in the pharmaceutical sector as of October 6, 2025.
€122.1 billion in 2024.There were generally no U.S. tariffs on pharmaceutical imports from Spain prior to the recent changes.
15%.Pharmaceutical products from Spain are subject to a U.S. import tariff of up to 15% under the terms of the recent EU-US trade agreement. This represents a new cost for Spanish pharmaceutical exporters to the U.S. market. The 15% cap is seen as a measure to prevent even higher potential tariffs.
Current U.S. tariff landscape for Brazil in the pharmaceutical sector as of October 6, 2025.
Information on pre-existing tariff rates for Brazilian pharmaceuticals is not available in the search results.
There is currently no indication of any recent changes to U.S. tariffs on pharmaceutical products from Brazil. The trade relationship in this sector appears to be stable and is not mentioned in the context of the recent protectionist measures announced by the U.S. It is likely that the standard Most-Favored-Nation (MFN) tariff rates apply.
Current U.S. tariff landscape for Slovenia in the pharmaceutical sector as of October 6, 2025.
$830 million due to tariffs, which is equivalent to 1.1% of Slovenia's annual GDP.Before the recent tariffs, pharmaceuticals from Slovenia were generally not subject to U.S. import duties.
15% for most pharmaceuticals. However, due to the composition of its exports, Slovenia could face a higher effective tariff rate.Slovenia's pharmaceutical industry has been significantly impacted by U.S. tariffs, largely due to its integration with the Swiss pharmaceutical supply chain, which faces high U.S. tariffs. While Slovenia is covered by the EU-US agreement capping tariffs at 15%, the indirect effects through its trade partners have been substantial. The economic impact of these tariffs on Slovenia's highly open economy is a significant concern.
Current U.S. tariff landscape for Mexico in the pharmaceutical sector as of October 6, 2025.
Tariffs on pharmaceuticals were mostly eliminated under the North American Free Trade Agreement (NAFTA), the predecessor to the USMCA.
The trade of pharmaceutical products between the United States and Mexico is governed by the USMCA, which provides for largely tariff-free trade. The recent U.S. tariff actions have been focused on overseas imports and have not impacted the preferential treatment of pharmaceuticals from Mexico under the USMCA. Thus, the tariff situation for pharmaceuticals remains stable in the U.S.-Mexico trade relationship.
Current U.S. tariff landscape for Australia in the pharmaceutical sector as of October 6, 2025.
$1.9 billion to $2.6 billion. In 2024, pharmaceuticals were Australia's third largest export to the US.Under the Australia-United States Free Trade Agreement (AUSFTA), most pharmaceutical trade was duty-free.
100% tariff on branded and patented pharmaceutical imports.100% on branded and patented pharmaceuticals, with exemptions for companies building or operating manufacturing plants in the U.S.The announced 100% U.S. tariff on branded pharmaceuticals poses a potential threat to Australia's pharmaceutical export industry. However, the impact may be mitigated by exemptions for companies with a U.S. manufacturing footprint, such as Australia's largest pharmaceutical exporter, CSL. The Australian government is currently working to understand the full implications of these new tariffs for local exporters.
Current U.S. tariff landscape for Sweden in the pharmaceutical sector as of October 6, 2025.
€122.1 billion in pharmaceutical exports to the U.S. in 2024.U.S. tariffs on pharmaceuticals from Sweden were generally zero before the recent trade agreement.
15%.Pharmaceuticals exported from Sweden to the United States are subject to a tariff of up to 15% under the recent EU-US trade agreement. This new tariff represents a shift from the previous duty-free environment. The 15% cap provides some measure of stability for the Swedish pharmaceutical industry in its trade with the U.S.